Risk Evaluation and Mitigation Strategies

A federal judge in Virginia ruled that the FDA's 2023 restrictions on mifepristone, a drug used to terminate early pregnancies, are unlawful due to insufficient justification. The ruling follows similar challenges from abortion providers in Kansas, Montana, and Virginia, who argued the restrictions—requiring special certifications and risk acknowledgment forms—are excessive and medically unnecessary.